Recent Updates
Recently added Catalysts
CORT Neutral Sentiment

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Tuesday, October 27, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Corcept Therapeutics will announce its third quarter financial results on November 3, 2026. The company will also provide a corporate update during this time. A conference call is scheduled for 5:00 p.m. Eastern Time, requiring advance registration for participants.

Market Sentiment Analysis

POSITIVE FACTORS

  • Corcept will report third quarter financial results.
  • A corporate update will be provided.
  • A conference call is scheduled for November 3.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+283%
120-day peak, hindsight
Typical move
12.9%
average across 6 past catalysts
Lead asset
CORT118335
Phase 1 · Antipsychotic-induced Weight Gain

Full Press Release Details

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique acces

Frequently Asked Questions

When will Corcept report its Q3 financial results?

Corcept will report its Q3 financial results on November 3, 2026.

What time is the conference call scheduled?

The conference call is scheduled for 5:00 p.m. Eastern Time.

Is registration required for the conference call?

Yes, participants must register in advance to receive dial-in information.

What will Corcept provide during the call?

Corcept will provide a corporate update during the conference call.

ShareAdd on Google
Tags: CORT Corcept Therapeutics financial results corporate update conference call
Last updated: Oct 27, 2026

Biotech snapshot

Cash runway
$545M liquidity · $0M/mo burn
Low dilution risk
Lead asset
CORT118335Phase 1
Antipsychotic-induced Weight Gain →

Catalyst track record

+283%
best trade around CORT's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CORT.

See every catalyst's timing & PoA →